Abstract:1049 Objectives There is evidence that patients with diabetes mellitus have an increased risk of developing Alzheimer disease. It’s hypothesized that advanced glycation end-products (AGEs) accumulate in the organs and tissues affected by chronic diabetes, thus leading to Alzheimer’s disease. AGEs can further activate a specific type of receptor called RAGE (receptor for advanced glycation end products), which is a subtype of immunoglobulin receptors. The objective of this study was to radiosynthesize 18F-FPS-ZM1, a RAGE-specific PET tracer which can be used to further explore the link between diabetes and Alzheimer’s disease, and to evaluate its biological characteristics. Methods We designed a new probe 18F-FPS-ZM1 targeted RAGE screened from thousands of small molecules. The precursor and standard reference compounds of 18F -FPS-ZM1 were synthesized and identified. We tested different radiolabeled methods and proposed automated radiosynthesis processes in the production of 18F-FPS-ZM1. The biodistribution of 18F-FPS-ZM1was determined ex vivo in healthy mice after intravenous injection. In addition, its biological characteristics, acute toxicity, as well as microPET imaging and autoradiography on dementia and diabetic models were evaluated. Results 18F -FPS-ZM1 was radiosynthesized with high radiochemical purity (>99%) and activity (30mCi/mL). 18F-FPS-ZM1is electrically neutral. The lipophilicity of 18F-FPS-ZM1 is determined by lipid-water partition coefficient (lgP), and the lgP is 1.87, indicating 18F-FPS-ZM1 is lipophilic. Radiochemical purity of 18F-FPS-ZM1 remains stable at the level about 100% up to 6 hours in PBS vitro, while radiochemical purity of 18F-FPS-ZM1 is 55% in serum. Meanwhile, our blood kinetic studies had shown that the distribution and elimination of 18F-FPS-ZM1 were coincident with the results given by compartment modeling. 18F-FPS-ZM1 was quickly distributed from blood to other organs (t1/2α= 1.38 min), and had relatively favorable retention time in target organs (t1/2β= 6.19 hour). The statistical moment parameters of t1/2 in female and male mice were 5.51h and 4.02h respectively. Biodistribution of 18F-FPS-ZM1 displayed high brain permeability in the beginning. Later on, 18F-FPS-ZM1 was cleared rapidly from C57BL/6J mice brains and most other organs (except for liver, cecum and gonad), indicating low non-specific binding in brain and those organs vivo. The uptake of female mice was higher than male mice in brain and other organs. Micro PET imaging indicated that the uptake of 18F-FPS-ZM1 in brain was higher in dementia models (B6C3-Tg(APPswe,PSEN1dE9)85Dbo/MmJNju) than in type 2 diabetic models (BKS.Cg-Dock7m +/+ Leprdb/JNju) and type 1 diabetic models. The results of autoradiography is coincident with Micro PET imaging, especially in hippocampus and cortex. The acute toxicity studies of [11C]-TKF was negative. Conclusions Alzheimer’s disease is a neuroendocrine disorder of the brain which currently has no effective treatment, bringing heavy burden to family and the society. There is evedence that AD is related to diabetes, yet the relationship is not clearly understood. In this work, we tested different radiolabeled methods and proposed automated radiosynthesis processes in the production of 18F-FPS-ZM1, a candidate which might be used to further explore the link between diabetes and Alzheimer’s disease. We evaluate a wide range of biological characterics of 18F-FPS-ZM1. With low molecular weight, 18F-FPS-ZM1 was stable, electrically neutral, lipophilic and non-mass concentration-dependent. Micro PET imaging and autoradiography indicate 18F-FPS-ZM1is a promising RAGE-specific probe. As potential brain imaging tracer. 18F-FPS-ZM1 might be a promising biomarker for early detection of Alzheimer9s disease for patients with diabetes.

Progress of RAGE Molecular Imaging in Alzheimer's Disease.

RAGE and Alzheimer's disease: a progression factor for amyloid-beta-induced cellular perturbation?

Advances of Molecular Imaging Probes for the Diagnosis of Alzheimer's Disease.

RAGE-AB Interactions in the Pathophysiology of Alzheimer's Disease

Aβ-AGE Aggravates Cognitive Deficit in Rats Via RAGE Pathway.

Current status of PET tracers for the early diagnosis of Alzheimer's disease

RAGE-specific probe 18F -FPS-ZM1 may be a promising biomarker for early detection of Diabetes with Alzheimer's disease

Alzheimer's Disease: Potential Pathogenesis and Imaging Findings

Past And Recent Progress Of Molecular Imaging Probes For Beta-Amyloid Plaques In The Brain

PET Neuroimaging of Alzheimer's Disease: Radiotracers and Their Utility in Clinical Research

Development of Near-Infrared Fluorescent Probes for Use in Alzheimers Disease Diagnosis

Development of Near-Infrared Fluorescent Probes for Use in Alzheimer’s Disease Diagnosis

A specific RAGE-binding peptide biopanning from phage display random peptide library that ameliorates symptoms in amyloid β peptide-mediated neuronal disorder

PET molecular imaging for pathophysiological visualization in Alzheimer's disease

Early Detection of Amyloid Pathology in Alzheimer's Disease by Molecular MRI

Molecular Imaging of Fluorinated Probes for Tau Protein and Amyloid-β Detection

Pathophysiology of Alzheimer’s Disease Revealed by Chemical Exchange Saturation Transfer MRI

Novel PET molecular probes for early diagnosis of Alzheimer's disease

RAGE Mediates Amyloid-Β Peptide Transport Across the Blood-Brain Barrier and Accumulation in Brain

PET Imaging of Neuroinflammation in Alzheimer's Disease

Pathological Mechanisms Linking Diabetes Mellitus and Alzheimer’s Disease: the Receptor for Advanced Glycation End Products (RAGE)